Table 4.
Comparison of adverse effects of the two treatment modalities
Adverse effect | Dry mouth | Dysuria | Vertigo | Xerophthalmia | Local inflammation | Enlarged breasts | Vaginal bleeding | Overall incidence |
---|---|---|---|---|---|---|---|---|
Tolterodine (n = 30) | 8 | 3 | 2 | 1 | 2 | 0 | 0 | 53% |
Intravaginal Estrogen (n = 28) | 0 | 1 | 1 | 0 | 3 | 0 | 2 | 25% |